23:03 , Aug 9, 2019 |  BC Extra  |  Company News

Allakos sustains its gains on strength of GI readout

Not even the dilution of an upsized follow-on offering could slow Allakos' momentum as its share price marched north steadily through midweek on the strength of Phase II data in eosinophilic gastrointestinal disorders, suggesting investors...
17:17 , Aug 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Blocking interaction between 'don't eat me signal' CD24 and SIGLEC10 to treat cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer; breast cancer A team led by FortySeven Inc. founder Irving Weissman showed inhibiting the interaction between CD24 on cancer cells and SIGLEC10 on tumor-associated macrophages (TAMs) could treat ovarian...
20:08 , Aug 5, 2019 |  BC Extra  |  Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target. Allakos Inc. (NASDAQ:ALLK)...
01:41 , Aug 2, 2019 |  BC Innovations  |  Translation in Brief

A charged system for insulin delivery

A charge-based glucose-binding switch is the latest technology aimed at enabling automatic insulin control. With proof-of-concept experiments in mice and minipigs, the system could rival preclinical technologies picked up by Eli Lilly, Merck and Novo...
23:29 , Aug 1, 2019 |  BC Extra  |  Preclinical News

Forty Seven sees combo opportunities for Weissman's latest ‘don't eat me’ signal

Forty Seven believes the latest study from founder Irving Weissman could point to combination strategies for blocking “don’t eat me signals” on tumors, but thinks inhibitors of the CD24-SIGLEC10 interaction described in the paper will...
21:55 , Jul 24, 2019 |  BC Innovations  |  Distillery Therapeutics

Simultaneous CLEC5A and TLR2 inhibition for dengue

DISEASE CATEGORY: Infectious disease INDICATION: Dengue fever; viral hemorrhagic fever Simultaneously blocking CLEC5A and TLR2, both pattern recognition receptors linked to microbial infections, could improve survival following dengue virus infection. The inflammatory response to dengue...
21:56 , Jul 23, 2019 |  BC Extra  |  Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
21:10 , May 9, 2019 |  BioCentury  |  Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...